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Background: Stroke is a potential complication of acute coronary syndrome (ACS). The aim of this study was to
identify the prevalence, risk factors predisposing to stroke, in-hospital and 1-year mortality among patients
presenting with ACS in the Middle East.
Methods: For a period of 9 months in 2008 to 2009, 7,930 consecutive ACS patients were enrolled from 65
hospitals in 6 Middle East countries.
Results: The prevalence of in-hospital stroke following ACS was 0.70%. Most cases were ST segment elevation
MI-related (STEMI) and ischemic stroke in nature. Patients with in-hospital stroke were 5 years older than patients
without stroke and were more likely to have hypertension (66% vs. 47.6%, P= 0.001). There were no differences
between the two groups in regards to gender, other cardiovascular risk factors, or prior cardiovascular disease.
Patients with stroke were more likely to present with atypical symptoms, advanced Killip class and less likely to be
treated with evidence-based therapies. Independent predictors of stroke were hypertension, advanced killip class,
ACS type –STEMI and cardiogenic shock. Stroke was associated with increased risk of in-hospital (39.3% vs. 4.3%)
and one-year mortality (52% vs. 12.3%).
Conclusion: There is low incidence of in-hospital stroke in Middle-Eastern patients presenting with ACS but with
very high in-hospital and one-year mortality rates. Stroke patients were less likely to be appropriately treated with
evidence-based therapy. Future work should be focused on reducing the risk and improving the outcome of this
devastating complication.
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Stroke is the second leading cause of death worldwide
and an estimated 795,000 persons have strokes in the
USA each year [1]. There appears to be geographic vari-
ation in the incidence of stroke and its recurrence even
within the same country [2]. The risk of developing* Correspondence: jalsuwaidi@hotmail.com
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distribution, and reproduction in any mediumstroke as a complication of acute coronary syndrome
(ACS) is uncommon, however although this risk is de-
creasing gradually, the mortality rate from this complica-
tion is high [3]. Several studies explored risk factors for
stroke after ACS and outcome, however these studies
were almost exclusively conducted in developed coun-
tries, and data from other ethnicities are lacking [1,3].
We have recently reported that Middle Eastern patients
presenting with ACS are relatively younger and are more
likely to have diabetes mellitus and metabolic syndrome
when compared to their western counterparts [4-6].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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may contribute to our understanding of this complica-
tion after ACS. Using data from the First Gulf Registry
of Acute Coronary Events (Gulf RACE) we have recently
reported low prevalence of stroke associated with high
in-hospital complication rates among patients presenting
acute myocardial infarction [7]. Here, we review the clin-
ical characteristics, in-hospital and 1-year outcome of
stroke patients across the whole spectrum of ACS using
data from the Gulf RACE-2.
Methods
Subjects
The data were collected from a 9-month prospective,
multicenter study of the 2nd Gulf Registry of Acute Cor-
onary Events (Gulf RACE) that recruited 7,939 consecu-
tive ACS patients from 6 adjacent Middle Eastern Gulf
countries (Bahrain, KSA, Qatar, Oman, United Arab
Emirates, and Yemen) between October 2008 and June
2009. Nine subjects were taken out from the study
due to non-ACS cases after final diagnosis. Patients
diagnosed with ACS, including unstable angina (UA)
and non-ST- and ST-elevation myocardial infarction
(NSTEMI and STEMI, respectively), were recruited from
65 hospitals. The study was conducted in compliance
with the Helsinki Declaration and ethical approval was
obtained the Institutional Review Board and Research
and Development Committees of the Ministries of
Health in Bahrain, Saudi Arabia, Oman, Qatar, United
Arab Emirates and Yemen [8].
On-site cardiac catheterization laboratory was avail-
able in 43% of the hospitals. There were no exclusion
criteria, and thus, all the prospective patients with ACS
were enrolled. The study received ethical approval from
the institutional ethical bodies in all participating coun-
tries [8]. Diagnosis of the different types of ACS and
definitions of data variables were based on the American
College of Cardiology clinical data standards [9].
A Case Report Form (CRF) for each patient with sus-
pected ACS was filled out upon hospital admission by
assigned physicians and/or research assistants working
in each hospital using standard definitions and was com-
pleted throughout the patient’s hospital stay. All CRFs
were verified by a cardiologist then sent on-line to the
principal coordinating center, where the forms were fur-
ther checked for mistakes before submission for final
analysis. An enquiry about patients’ survival at 1 and
12 months follow-up after discharged was made.
Definitions
Stroke was defined as neurologic deficit persisting more
than 24 hours. Stroke types; hemorrhagic a stroke with
documentation on imaging of hemorrhage in the cere-
bral parenchyma, or subarachnoid hemorrhage, Ischemic;a focal neurologic deficit that results from a thrombus
or embolus (and not due to hemorrhage) or Unknown; if
the type of stroke could not be determined by imaging
or other means (e.g. from lumbar puncture) or if im-
aging was not performed [7,10].
Statistical analysis
Univariate comparisons of patients with and without
strokes were made. Continuous variables are presented as
means and Standard deviations and compared using the
student t tests or Wilcoxon rank sum tests wherever ap-
plicable. Categorical variables are shown as percentages,
and compared using the Chi-square tests. Bivariate logis-
tics regressions were used taking age, gender, smoking,
diabetes mellitus, hypertension, dyslipidemia, systolic
blood pressure, heart rate, creatinine, atrial fibrillation,
prior MI, prior CABG, peripheral vascular disease, killip
class, ACS type, cardiogenic shock, prior aspirin and statin
independent variables to see association with in-hospital
stroke, in-hospital mortality and one year mortality. Multi-
variate logistic regressions with forward selection were ap-
plied taking significant predictors at p <=0.10 in bivariate
analysis for stroke, in-hospital and one year mortality. Un-
adjusted and adjusted odds ratios (OR) and 95% C.I. were
calculated. P value < 0.05 (two tailed) was considered sta-
tistically significant at multivariate analysis. Only final
multivariate analyses results are provided for in-hospital
and one year mortality. Restricted cubic spline functions
between SBP and stroke, and SBP and mortality are
checked taking quartiles knots of SBP. All analyses were
performed using SPSS 18.0 Statistical Package licensed by
HMC, Doha, Qatar.
Results
Of 7,930 patients with ACS in the present analysis,
45.6% had STEMI and 54.4% had non-ST elevation acute
coronary syndrome. Fifty-six patients (0.7%) suffered
stroke during their index hospitalization. Stroke patients
were more likely to present with ST-elevation myocar-
dial infarction (STEMI) (n = 40) and less likely to present
with NSTEMI (n = 10) and unstable angina (n = 6). In-
hospital stroke was classified as ischemic in 29 patients
(52%). Hemorrhagic stroke occurred in 19 patients
(34%), while in the remaining 8 patients (14%) stroke
type was not identified.
Baseline characteristics of patients with stroke
(Table 1).
Patients who suffered in-hospital stroke were about
5 years older than patients without stroke (62 ± 12 vs.
57 ± 12, P =0.006). Stroke patients were less likely to
have dyslipidemia (34.8% vs. 37.5%, P= 0.001) but were
more likely to have hypertension (66% vs. 47.6%,
P= 0.01) and atrial fibrillation (7.1% vs. 2.1%, P= 0.008).
Stroke patients were more likely and to present
Table 1 Baseline demographics and clinical characteristics for patients with or without prior stroke
Variable No stroke (n= 7,874 ) Stroke (n= 56) P value
Diagnosis
STEMI / New or presumed LBBB 45.4% 71.4% 0.001
NSTEMI 30.2% 17.9%
Unstable Angina 24.4% 10.7%
Age in years (mean± SD) 57 ± 12 62 ± 12 0.006
Female gender 21.2% 25% 0.5
Body mass index (kg/m2) (mean± SD) 27 ± 5 26 ± 4 0.20
Current smokers 52.9% 51.8% 0.9
Previous angina 38.4% 45.3% 0.30
Previous MI 19.8% 20.8% 0.86
Previous PCI 9.2% 5.6% 0.35
Previous CABG 4.3% 3.6% 0.8
Diabetes mellitus* 40.1% 43.6% 0.6
Hypertension† 47.6% 66% 0.01
Hyperlipidemia{ 37.5% 34.8% 0.001
Family history of CAD 11.7% 8.7% 0.53
Previous heart failure 6.7% 13.2% 0.06
Atrial fibrillation 2.1% 7.1% 0.008
Renal failure 4.1% 3.7% 0.89
Peripheral arterial disease 2% 4% 0.26
At presentation
Presentation >12 hours 58.4% 41.7% 0.1
Ischemic chest pain 84.3% 62.5% 0.001
Atypical chest pain 5% 3.6%
Dyspnea 7% 10.7%
Killip Class 0.001
Killip class I 77.2% 53.6%
Killip class II 14.4% 28.6%
Killip class III 5.1% 5.4%
Killip class IV 3.2% 12.5%
Heart rate (beats/min) (mean± SD) 84 ± 20 90 ± 19 0.05
Systolic blood pressure (mm Hg) (mean± SD) 135 ± 29 132 ± 35 0.44
Diastolic blood pressure (mm Hg) (mean± SD) 81 ± 17 90 ± 19 0.05
GRACE risk score




Aspirin 40.5% 43.6% 0.4
Clopidogrel 12.4% 8.9% 0.4
Β-blockers 29.1% 25% 0.5
ACE inhibitors 25.6% 33.9% 0.2
Angiotensin-receptor blockers 4.7% 1.8% 0.3
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Table 1 Baseline demographics and clinical characteristics for patients with or without prior stroke (Continued)
HMG-CoA reductase inhibitor 31.5% 30.4% 0.9
Laboratory investigations
Creatinine 101 ± 74 140 ± 124 0.03
Data are expressed as mean or as number (percentage).
* Patient had been informed of the diagnosis by a physician before admission and was undergoing treatment for type 1 or 2 diabetes.
† Systolic blood pressure >140 mm Hg, diastolic blood pressure >90 mm Hg, or current antihypertensive treatment.
ACE-inhibitors = angiotensin-converting enzyme inhibitors.
{ Total cholesterol >6.1 mmol/L, low-density lipoprotein >4.1 mmol/L, or high-density lipoprotein <0.9 mmol/L; triglycerides >200 mg/dl; or current use of lipid-
lowering agent; MI =myocardial infarction; PCI = percutaneous coronary intervention; CAD= coronary artery diseases; CABG=Coronary Artery Bypass Graft.
Al Suwaidi et al. BMC Cardiovascular Disorders 2012, 12:64 Page 4 of 9
http://www.biomedcentral.com/1471-2261/12/64with atypical cardiac symptoms , advanced Killip class
II-IV (P= 0.001), higher heart rate (90 vs. 84 beat per
minute, P= 0.05), diastolic blood pressure (90 ± 19 vs.
81 ± 17 mmHg; P= 0.05) and GRACE risk scoring. There
were no significant differences between the two groups
in regards to the prevalence of diabetes mellitus, smok-
ing, previous cardiovascular disease, renal failure, per-
ipheral arterial disease or systolic blood pressure. Prior
aspirin, clopidogrel, Β-blockers, vasodilators and statins
were comparable between the 2 groups. Serum creatin-
ine was significantly elevated among stroke when
compared to non-stroke patients.
In-hospital Treatment patterns of patients with
stroke (Table 2).
The treatment patterns for patients with stroke are
presented in Table 2. Stroke patients were less likely toTable 2 In-hospital therapy and at discharge in patients with
During admissio
No stroke Stroke
(n= 7,874) (n = 56)
Coronary angiography 32.6% 12.5%*
Percutaneous coronary intervention 14.5% 5.4%
Elective 10.2% 1.8%
Urgent/Emergency PCI (UA/NSTEMI) 4.2% 3.6%
Aspirin 98% 91%
β blockers 75% 46%
Clopidogrel 76% 55%
ACE inhibitors 25.6% 33.9%
Angiotensin receptor blockers 4.7% 1.8%
HMG-CoA reductase inhibitor 95% 89%






Unfractionated heparin 49.5% 33.9%
LMWH (enoxaparin) 39.1% 21.4%
Data are expressed as percentage; STEMI = ST elevation myocardial infarction; NSTE
bundle branch block; PCI = percutaneous coronary intervention; LVEF = left ventricube treated with aspirin, clopidogrel, unfractionated hep-
arin, low molecular weight heparin, glycoprotein IIb/IIIa
inhibitors or thrombolytic therapy. Overall use of coron-
ary angiography was low in our registry and its use was
even lower among patients who had stroke (12.5% vs.
32.6%). Similar results were found in elective (1.8% vs.
10.2%) and emergency (3.6% vs. 4.2%) percutaneous cor-
onary interventions (PCI). Stroke patients who were dis-
charged alive were less likely to be prescribed aspirin,
clopidogrel, Β-blockers, ACE inhibitors and statins at
discharge.
In-hospital and One-year outcomes of patients with
stroke (Table 3, Figure 1).
Patients who suffered in-hospital stroke were more
likely to have their hospital course complicated with re-
current myocardial ischemia (32% vs. 15%), recurrentor without stroke
n At discharge
P value No stroke Stroke P value




0.001 93% 57% 0.001
0.001 80% 38% 0.001
0.001 68% 38% 0.001
0.16 72% 47% 0.001
0.30 6.8% 1.8% 0.1





MI = non ST elevation myocardial infarction; UA = unstable angina; LBBB = left
lar ejection fraction.
Table 3 In-hospital and one-year outcomes of patients with or without stroke ACS patients
Variable No stroke (n = 7,874 ) Stroke (n = 56) P value
Hospital outcome
Recurrent ischemia 15% 32% 0.001
Reinfarction 2% 10.7% 0.001
Congestive heart failure 12.9% 39.3% 0.001
Cardiogenic shock 34% 5.6% 0.001
Major bleeding 0.5% 12.5% 0.001
Predischarge echocardiogram (LVEF < 30) 76.5% 71.4% 0.37
Hospital stay (days) 5.9 ± 6 13.45 ± 14 0.001
Mortality
In-hospital 4.3% 39.3% 0.001
30 day 7.9% 46.3% 0.001
One year 12.3% 52% 0.001
Data are expressed as percentage; STEMI = ST elevation myocardial infarction; NSTEMI = non-ST elevation myocardial infarction; UA= unstable angina; LBBB = left
bundle branch block; PCI = percutaneous coronary intervention; LVEF = left ventricular ejection fraction.
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(34% vs. 5.6%) and major bleeding (12.5% vs. 0.5%) com-
pared to those without stroke. Death occurred in 39.3%
of patients who suffered in-hospital stroke compared to
4.3% of those who did not. Length of stay was signifi-
cantly longer among stroke compared to non-stroke
patients (13.5 vs. 5.9 days; P= 0.001).
The mortality rate at one month (46.3% vs. 7.9%;
P= 0.001) and one year (52% vs. 12.3%; P= 0.001) were
significantly higher among stroke patients when com-
pared to non-stroke patients.
Stroke Subtypes (Table 4).
Subset analysis revealed no significant differences be-
tween the 3 stroke subtypes in regards to baseline clin-
ical characteristics, MI types or therapies, although there
was a trend of increased hemorrhagic stroke among
patients treated with thrombolytic therapy.
Multivariate predictors of stroke (Table 5).
Bivariate results showed age (OR=1.03, 95% C.I.:1.01-












Figure 1 In-hospital, one month and one year mortality rate
according to the presence and absence of stroke among acute
coronary syndrome patients.Atrial fibrillation (OR= 3.70, 95% C.I.:1.30-10.0);
advanced killip class >1 (OR=2.95, 95% C.I.: 1.73-5.0);
ACS type STEMI (OR= 3, 95% C.I.: 1.68-5.38); and car-
diogenic shock (OR= 9.15, 95% C.I: 5.19-16.12) signifi-
cant variables whereas; advanced killip class, history of
hypertension, STEMI and cardiogenic shock were found
associated with increased risk of in-hospital stroke in
multivariate analysis.
Multivariate predictors of in-hospital death
(Table 6).
All Independent Variables having p < =0.10 at bivariate
analysis for in-hospital mortality were considered for
multivariate analysis. In-hospital stroke was found inde-
pendently associated with a significantly higher risk of
in-hospital death. The odds of mortality was 42 times
higher with 95% C.I. (4.09 – 426.7) in patients with
stroke compared to those without stroke.
Multivariate predictors of one-year mortality
(Table 7).
At one year also stroke was found independently asso-
ciated with a significantly higher risk of mortality having
OR=13.0 and 95% C.I (1.91-81.9) in stroke patients in
comparison to non-stroke.Discussion
The current study reports low prevalence of stroke
among Middle Eastern patients presenting with ACS.
52% of these strokes were ischemic in origin and 14%
were hemorrhagic. Risk factors of stroke were older age,
STEMI presentation, atrial fibrillation and history of
hypertension. Stroke patients were less likely to be
appropriately treated with evidence-based therapy
during hospitalization and at discharge. Although the
prevalence of stroke was low and comparable to that
of reported registries in Western countries, the
Table 4 Clinical Characteristics and therapy according to stroke subtypes
Ischemic Hemorrhagic Not identified P-value
No (%) 29(52%) 19 (34%) 8(14%)
Age 60.5 ± 12 60 ± 11 67 ± 15 0.41
Gender Female 10(34.5) 2(10.5) 2(25) 0.17
Diabetes Mellitus 16(52.2) 7(36.8) 1(12.5) 0.08
Hypertension 20(69) 9(47.4) 6(75) 0.23
Atrial fibrillation 4(13.8) 0(0) 0(0) 0.14
Heart rate 92 ± 19 89.9 ± 15 83 ± 30 0.54
Systolic blood pressure 132 ± 30 139± 35 116± 50 0.29
Diastolic blood pressure 76 ± 24 84 ± 19 68 ± 32 0.28
STEMI 20(69) 16(84.2) 4(50)
NSTEMI 6(20.7) 1(5.3) 3(37.5)
UA 3(0.3) 2(10.5) 1(12.5) 0.34
Coronary Angiogram 5(17.2) 1(5.3) 1(12.5) 0.30
PCI 2(6.9) 1(5.3) 0(0) 0.47
Medications on admission
Thrombolytic therapy 10(52.6) 5(31.2) 0(0) 0.11
Glycoprotein IIb/III inhibitors 12(41.4) 7(36.8) 6(75) 0.17
aspirin 26(89.7) 17(89.5) 8(100) 0.63
Clopidogrel 15(51.7) 6(31.6) 4(50) 0.37
Table 5 Bivariate and multivariate logistic regression with forward selection for in-hospital stroke patients with acute
coronary syndrome
Variables Unadjusted OR 95% C.I. Adjusted OR 95% C.I.
Age 1.03 1.01 – 1.05 – –
Gender Female 1.24 0.67 – 2.27 – –
Smoking 0.78 0.44 – 1.39 – –
Diabetes mellitus 1.16 0.68 – 1.97 – –
Hypertension 1.87 1.09 – 3.22 2.75 1.50 – 5.26
Dyslipidemia 0.89 0.50 – 1.6 – –
Systolic Blood Pressure
<=120 mmgh 1
121-150 mmgh 1.22 0.66 – 2.26 – –
>= 151 mmgh 1.09 0.54 – 2.22 – –
Heart rate (beets /minute) 1.01 1.00 – 1.02 – –
Creatinine (mg/dl) 1.06 0.69 – 0.84 – –
Atrial Fibrillation 3.70 1.30 – 10.0 – –
Prior MI 1.06 0.50 – 2.01 – –
Prior CABG 0.83 0.20 – 3.40 – –
Peripheral Vascular Disease 2.00 0.50 – 8.00 – –
Killip Class > 1 2.95 1.73 – 5.00 1.90 1.03 – 3.50
ACS type Stemi/LBBB 3.00 1.68 – 5.38 2.94 1.56 – 5.52
Cardiogenic Shock 9.15 5.19 – 16.12 5.72 2.96 – 11.04
Prior Aspirin 1.30 0.78 – 2.28 – –
Statin within 24 hrs 0.50 0.20 – 1.07 – –
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Table 6 Predictors of in-hospital mortality in ACS patients
according to Multivariate logistic regression with forward
selection
Variables In-hospital mortality
Adjusted OR 95% C.I.
Creatinine (mg/dl) 1.47 1.27 – 1.70
Cardiogenic Shock 85.48 34.5 – 212.0
Stroke 41.75 4.09 – 426.7
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46% in-hospital mortality and 52% one-year mortality
rates.
The reported prevalence of stroke from studies per-
formed mainly in the Western world varied between as
low as 0.31% to 1.9% [9-30]. The advent of thrombolysis
and primary PCI undoubtedly resulted in significant re-
duction in stroke risk from 5% in the 1970s to 1% in the
current era. The current study reports 0.7% stroke
prevalence among Middle Eastern patients presenting
with ACS patients in the current era which consistent
with previous reports. On the other hand, Ng et al. [19]
reported a 7.2% one-year risk of stroke among small
population of Chinese MI patients, which is much
higher than other reports including ours from a previous
registry [7]. When compared to the current study, stroke
patients in the National Registry of Myocardial Infarc-
tion (NRMI) 3&4 and the Wercester Heart Attack Study
were significantly older (>10 yrs) and less likely to have
diabetes mellitus [3,17]. Also, while thrombolysis is the
main modality of reperfusion therapy in the current
registry, significantly more patients received primary PCI
in the other studies. The current study suggests that the
reduction in stroke risk most likely related to the overall
improvement in health care including the provision of
evidence-based therapy regardless of the primary reper-
fusion therapy.
Older age, systemic hypertension, dyslipidemia and
ST-elevation myocardial infarction were independentTable 7 Predictors of one year mortality according to
Multivariate logistic regression with forward selection in
ACS patients
Variables One year mortality
Adjusted OR 95% C.I.
Age 1.03 1.01 – 1.05
Diabetes Mellitus 1.64 1.05 – 2.56
Creatinine (mg/dl) 1.50 1.25 – 1.82
Atrial Fibrillation 5.01 1.09 – 23.1
Killip Class >1 1.97 1.22 – 3.18
Cardiogenic Shock 8.08 4.09 – 15.9
Stroke 12.53 1.91 – 81.9risk factors of stroke in our registry. This is consistent
with some of the previous reports. Other independent
risk factors previously reported in other reports include
prior or in-hospital CABG, renal impairment, low
body weight and elevated admission heart rate [11-32].
These variability in findings may be attributed to several
factors including patients’ population, ethnicities, use
of thrombolytic therapy versus primary percuatenous
revascularization therapy and underscore the need of
further international studies that include adequate repre-
sentations of female gender and various ethnicities [33].
There were no significant differences between patients
according to their stroke subtypes in regards to clinical
characterstics, MI types or therapies although there a
trend of higher use of thrombolytic therapy among
hemorrhagic stroke patients.
We observed 39.3% in-hospital mortality among stroke
patients, which is almost 10 times higher than ACS who
did not develop stroke. This suggests that although
therapeutic advancement in the management of ACS
patients has resulted in remarkable improvement in out-
come, this improvement in outcome unfortunately was
not observed among stroke patients, this underscores
the urgent need to study ways to improve this outcome.
This is consistent with pervious reports from the devel-
oped world, which observed a mortality rate from ische-
mic stroke of up to 10-40%, and even higher with
hemorrhagic stroke. Stroke patients among our patients
population were less likely to be treated with evidence-
based therapy at admission and on discharge, which may
contribute to the high mortality rate at one-year follow-
up. These observations are consistent with that reported
by Lee TC et al. [33].
Limitations
Our data were collected from an observational study.
The fundamental limitations of observational studies
cannot be eliminated because of the nonrandomized na-
ture and unmeasured confounding factors. However,
well-designed observational studies provide valid results
and do not systemically overestimate the results com-
pared with the results of randomized controlled trials.
We did not look for risk factors by day of onset. Stroke
occurring within first few days may be different from
those occurring a week or two later.
Conclusion
The current study reports low prevalence of stroke
among Middle Eastern ACS patients with very high in-
hospital mortality rate. While older age, anterior MI,
hypertension and dyslipidemia at admission were asso-
ciated with increased risk. Future work should be fo-
cused on reducing the risk and outcome of this
devastating complication.
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